Identification

Name
Cabazitaxel
Accession Number
DB06772
Type
Small Molecule
Groups
Approved
Description

Cabazitaxel is an anti-neoplastic used with the steroid medicine prednisone. Cabazitaxel is used to treat people with prostate cancer that has progressed despite treatment with docetaxel. Cabazitaxel is prepared by semi-synthesis with a precursor extracted from yew needles (10-deacetylbaccatin III). It was approved by the U.S. Food and Drug Administration (FDA) on June 17, 2010.

Structure
Thumb
Synonyms
  • Cabazitaxelum
  • Taxoid XRP6258
  • TXD258
  • XRP6258
External IDs
RPR-116258A / RPR116258 / TXD 258 / TXD-258 / XRP 6258 / XRP-6258
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
JevtanaSolution40 mgIntravenousSanofi Aventis2011-08-23Not applicableCanada
JevtanaKitSanofi Aventis2010-06-17Not applicableUs
Categories
UNII
51F690397J
CAS number
183133-96-2
Weight
Average: 835.9324
Monoisotopic: 835.377905537
Chemical Formula
C45H57NO14
InChI Key
BMQGVNUXMIRLCK-OAGWZNDDSA-N
InChI
InChI=1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1
IUPAC Name
(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0³,¹⁰.0⁴,⁷]heptadec-13-en-2-yl benzoate
SMILES
[H][[email protected]@](O)([[email protected]@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1)C(=O)O[[email protected]@]1([H])C[[email protected]@]2(O)[[email protected]@]([H])(OC(=O)C3=CC=CC=C3)[[email protected]]3([H])[[email protected]@]4(CO[[email protected]]4([H])C[[email protected]]([H])(OC)[[email protected]@]3(C)C(=O)[[email protected]]([H])(OC)C(=C1C)C2(C)C)OC(C)=O

Pharmacology

Indication

For treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.

Structured Indications
Pharmacodynamics

Cabaitaxel has anti-tumour properties and is effective against docetaxel-sensitive and -insensitive tumours.

Mechanism of action

Cabazitaxel is a microtubule inhibitor. Cabazitaxel binds to tubulin and promotes its assembly into microtubules while simultaneously inhibiting disassembly. This leads to the stabilization of microtubules, which results in the interference of mitotic and interphase cellular functions. The cell is then unable to progress further into the cell cycle, being stalled at metaphase, thus triggering apoptosis of the cancer cell.

TargetActionsOrganism
ATubulin alpha-4A chain
binder
Human
ATubulin beta-1 chain
binder
Human
Absorption

After an intravenous dose of cabazitaxel 25 mg/m2 every three weeks to a population of 170 patients with solid tumors, the mean Cmax in patients with metastatic prostate cancer was 226 ng/mL (CV 107%) and was reached at the end of the one-hour infusion (Tmax). The mean AUC in patients with metastatic prostate cancer was 991 ng.h/mL (CV 34%). Administration with prednisone or prednisolone do not effect the pharmacokinetic profile of cabazitaxel.

Volume of distribution

The volume of distribution (Vss) was 4,864 L (2,643 L/m2 for a patient with a median BSA of 1.84 m2) at steady state. Compared to other taxanes, penetrates the CNS to a greater extent.

Protein binding

Cabazitaxel is mainly bound to human serum albumin (82%) and lipoproteins (88% for HDL, 70% for LDL, and 56% for VLDL).

Metabolism

Cabazitaxel is extensively metabolized in the liver (>95%), mainly by the CYP3A4/5 isoenzyme (80% to 90%), and to a lesser extent by CYP2C8 which results in 20 different metabolites. Two of these metabolites are active demethylated derivatives of cabaxitaxel and referred to as RPR112698 and RPR123142 respectively. Docetaxel is another metabolite of cabazitaxel. Cabazitaxel is the main circulating moiety in human plasma.

Route of elimination

After a one-hour intravenous infusion [14C]-cabazitaxel 25 mg/m2, approximately 80% of the administered dose was eliminated within 2 weeks. Cabazitaxel is mainly excreted in the feces as numerous metabolites (76% of the dose); while renal excretion of cabazitaxel and metabolites account for 3.7% of the dose (2.3% as unchanged drug in urine).

Half life

Following a one-hour intravenous infusion, plasma concentrations of cabazitaxel can be described by a three-compartment pharmacokinetic model with α-, β-, and γ- half-lives of 4 minutes, 2 hours, and 95 hours, respectively.

Clearance

Cabazitaxel has a plasma clearance of 48.5 L/h (CV 39%; 26.4 L/h/m2 for a patient with a median BSA of 1.84 m2) in patients with metastatic prostate cancer.

Toxicity

Cabazitaxel may cause serious side effects including neutropenia, hypersensitivity reactions, gastrointestinal symptoms, and renal failure. Anticipated complications of overdose include exacerbation of adverse reactions such as bone marrow suppression and gastrointestinal disorders. Cabazitaxel penetrates the blood-brain barrier. LD50, rat = 500 mg/kg

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
10-hydroxycamptothecinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with 10-hydroxycamptothecin.Investigational
2-(4-Chlorophenyl)-5-QuinoxalinecarboxamideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.Experimental
2-chloroethyl-3-sarcosinamide-1-nitrosoureaThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with 2-chloroethyl-3-sarcosinamide-1-nitrosourea.Investigational
2-MethoxyestradiolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with 2-Methoxyestradiol.Investigational
3-MethoxybenzamideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with 3-Methoxybenzamide.Experimental
3,3'-diindolylmethaneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with 3,3'-diindolylmethane.Investigational
3,4-Dihydroxybenzoic AcidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with 3,4-Dihydroxybenzoic Acid.Experimental
6-O-benzylguanineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with 6-O-benzylguanine.Investigational
7-HydroxystaurosporineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with 7-Hydroxystaurosporine.Experimental, Investigational
8-azaguanineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with 8-azaguanine.Experimental
9-aminocamptothecinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with 9-aminocamptothecin.Investigational
AbirateroneThe serum concentration of Cabazitaxel can be increased when it is combined with Abiraterone.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Cabazitaxel.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Cabazitaxel.Experimental
AclarubicinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Aclarubicin.Investigational
Acridine CarboxamideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Acridine Carboxamide.Investigational
ActeosideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Acteoside.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Cabazitaxel.Approved
AfimoxifeneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Afimoxifene.Investigational
AfliberceptThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Aflibercept.Approved
AlatrofloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Alatrofloxacin.Withdrawn
AlbendazoleThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Aldesleukin.Approved
AlectinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Alectinib.Approved
AlemtuzumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Alemtuzumab.Approved, Investigational
AlitretinoinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Alitretinoin.Approved, Investigational
AltretamineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Altretamine.Approved
AlvocidibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Alvocidib.Experimental, Investigational
AminoglutethimideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Aminoglutethimide.Approved, Investigational
Aminolevulinic acidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Aminolevulinic acid.Approved
AmiodaroneThe serum concentration of Cabazitaxel can be increased when it is combined with Amiodarone.Approved, Investigational
AmonafideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Amonafide.Investigational
AmrubicinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Amrubicin.Approved, Investigational
AmsacrineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Amsacrine.Approved
AnagrelideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Anagrelide.Approved
AnastrozoleThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Anastrozole.Approved, Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Anecortave.Investigational
annamycinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with annamycin.Investigational
AP 12009The risk or severity of adverse effects can be increased when Cabazitaxel is combined with AP 12009.Investigational
AP24534The risk or severity of adverse effects can be increased when Cabazitaxel is combined with AP24534.Investigational
ApaziquoneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Apaziquone.Investigational
AprepitantThe serum concentration of Cabazitaxel can be increased when it is combined with Aprepitant.Approved, Investigational
Arotinoid acidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Arotinoid acid.Experimental
Arsanilic acidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Arsanilic acid.Experimental, Vet Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Arsenic trioxide.Approved, Investigational
AsparaginaseThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Asparaginase.Approved
AtazanavirThe serum concentration of Cabazitaxel can be increased when it is combined with Atazanavir.Approved, Investigational
AtezolizumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Atezolizumab.Approved
AtomoxetineThe metabolism of Cabazitaxel can be decreased when combined with Atomoxetine.Approved
AxitinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Axitinib.Approved, Investigational
AzacitidineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Azacitidine.Approved, Investigational
AzathioprineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Azathioprine.Approved
Azelaic AcidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Azelaic Acid.Approved
BatimastatThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Batimastat.Experimental
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Cabazitaxel.Investigational
BelinostatThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Belinostat.Approved, Investigational
BelotecanThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Belotecan.Investigational
BendamustineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bendamustine.Approved, Investigational
BesifloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Besifloxacin.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Cabazitaxel.Approved, Investigational
BexaroteneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bexarotene.Approved, Investigational
BicalutamideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bicalutamide.Approved
BinetrakinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Binetrakin.Investigational
BizelesinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bizelesin.Investigational
BleomycinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bleomycin.Approved
BlinatumomabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Blinatumomab.Approved
BoceprevirThe serum concentration of Cabazitaxel can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Cabazitaxel can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Cabazitaxel.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Cabazitaxel.Approved
BroxuridineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Broxuridine.Investigational
Bryostatin 1The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bryostatin 1.Investigational
BSI-201The risk or severity of adverse effects can be increased when Cabazitaxel is combined with BSI-201.Investigational
BuserelinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Buserelin.Approved
BusulfanThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Busulfan.Approved, Investigational
Buthionine SulfoximineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Buthionine Sulfoximine.Investigational
CabergolineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cabergoline.Approved
CabozantinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cabozantinib.Approved
CalcipotriolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Calcipotriol.Approved
CamptothecinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Camptothecin.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Canertinib.Investigational
CapecitabineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Cabazitaxel can be increased when combined with Carbamazepine.Approved, Investigational
CarboplatinCarboplatin may increase the myelosuppressive activities of Cabazitaxel.Approved
CarboquoneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Carboquone.Experimental
CarboxyamidotriazoleThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Carboxyamidotriazole.Investigational
CarfilzomibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Carfilzomib.Approved
CarmofurThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Carmofur.Withdrawn
CarmustineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Carmustine.Approved
CatumaxomabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Catumaxomab.Approved, Investigational
CediranibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cediranib.Investigational
CelecoxibThe metabolism of Cabazitaxel can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Cabazitaxel can be increased when it is combined with Ceritinib.Approved
CetuximabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cetuximab.Approved
ChlorambucilThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Chlorambucil.Approved
ChlorotrianiseneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Chlorotrianisene.Investigational, Withdrawn
CholesterolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cholesterol.Experimental, Investigational
CinoxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ciprofloxacin.Approved, Investigational
CisplatinCisplatin may increase the myelosuppressive activities of Cabazitaxel.Approved
CladribineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cladribine.Approved, Investigational
ClarithromycinThe serum concentration of Cabazitaxel can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Cabazitaxel can be decreased when combined with Clemastine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Clofarabine.Approved, Investigational
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cabazitaxel.Approved
ClotrimazoleThe metabolism of Cabazitaxel can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Clozapine.Approved
CobicistatThe serum concentration of Cabazitaxel can be increased when it is combined with Cobicistat.Approved
CobimetinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cobimetinib.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Cabazitaxel.Approved
CombretastatinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Combretastatin.Investigational
ConivaptanThe serum concentration of Cabazitaxel can be increased when it is combined with Conivaptan.Approved, Investigational
CordycepinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cordycepin.Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cabazitaxel.Approved
Coumermycin A1The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Coumermycin A1.Experimental
CrenolanibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Crenolanib.Investigational
CrisaboroleThe metabolism of Cabazitaxel can be decreased when combined with Crisaborole.Approved
CrizotinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Curcumin.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Cabazitaxel.Approved, Investigational
CyclosporineThe metabolism of Cabazitaxel can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Cabazitaxel.Experimental
Cyproterone acetateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cyproterone acetate.Approved, Investigational
CytarabineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cytarabine.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cabazitaxel.Approved
DabrafenibThe serum concentration of Cabazitaxel can be decreased when it is combined with Dabrafenib.Approved
DacarbazineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Dacarbazine.Approved, Investigational
DactinomycinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Dactinomycin.Approved
DaratumumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Daratumumab.Approved
DarunavirThe serum concentration of Cabazitaxel can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Cabazitaxel can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Daunorubicin.Approved
DecitabineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Decitabine.Approved, Investigational
DeferasiroxThe serum concentration of Cabazitaxel can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Degarelix.Approved
DelavirdineThe metabolism of Cabazitaxel can be decreased when combined with Delavirdine.Approved
DemecolcineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Demecolcine.Experimental
Denileukin diftitoxThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Denileukin diftitox.Approved, Investigational
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Cabazitaxel.Approved
DeoxyspergualinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Deoxyspergualin.Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Cabazitaxel.Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexrazoxaneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Dexrazoxane.Approved, Withdrawn
DianhydrogalactitolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Dianhydrogalactitol.Investigational
DidoxThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Didox.Investigational
DienogestThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Dienogest.Approved
diethylnorspermineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with diethylnorspermine.Investigational
DiethylstilbestrolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Diethylstilbestrol.Approved, Investigational
DigitoxinDigitoxin may decrease the cardiotoxic activities of Cabazitaxel.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Cabazitaxel.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Cabazitaxel.Approved
DihydroergotamineThe metabolism of Cabazitaxel can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Cabazitaxel can be decreased when combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Dinutuximab.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cabazitaxel.Approved, Investigational
Dolastatin 10The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Dolastatin 10.Investigational
DoxifluridineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Doxifluridine.Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Cabazitaxel.Approved, Investigational
DoxorubicinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Cabazitaxel can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Cabazitaxel can be decreased when combined with Dronedarone.Approved
DuligotuzumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Duligotuzumab.Investigational
EcabetThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ecabet.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Cabazitaxel.Approved
EdrecolomabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Edrecolomab.Experimental, Investigational
EfaproxiralThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Efaproxiral.Investigational
EfatutazoneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Efatutazone.Investigational
EfavirenzThe metabolism of Cabazitaxel can be decreased when combined with Efavirenz.Approved, Investigational
EflornithineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Eflornithine.Approved, Withdrawn
EG009The risk or severity of adverse effects can be increased when Cabazitaxel is combined with EG009.Investigational
ElotuzumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Elotuzumab.Approved
ElsamitrucinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Elsamitrucin.Investigational
EndostatinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Endostatin.Investigational
EnoxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Enoxacin.Approved, Investigational
EnrofloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Enrofloxacin.Vet Approved
EntinostatThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Entinostat.Investigational
EnzalutamideThe serum concentration of Cabazitaxel can be decreased when it is combined with Enzalutamide.Approved
Epigallocatechin GallateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Epigallocatechin Gallate.Investigational
EpirubicinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Epirubicin.Approved
EpofolateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Epofolate.Investigational
EribulinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Eribulin.Approved, Investigational
ErlotinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Erlotinib.Approved, Investigational
ErythromycinThe metabolism of Cabazitaxel can be decreased when combined with Erythromycin.Approved, Vet Approved
EstramustineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Estramustine.Approved
EtanidazoleThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Etanidazole.Investigational
Ethiodized oilThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ethiodized oil.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ethyl carbamate.Withdrawn
EtoglucidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Etoglucid.Experimental
EtoposideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Etoposide.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Cabazitaxel.Approved
ExatecanThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Exatecan.Investigational
ExemestaneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Exemestane.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with exisulind.Investigational
FelodipineThe metabolism of Cabazitaxel can be decreased when combined with Felodipine.Approved, Investigational
FenretinideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fenretinide.Investigational
FiacitabineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fiacitabine.Investigational
FingolimodCabazitaxel may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fleroxacin.Approved
FloxuridineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Floxuridine.Approved
FluconazoleThe metabolism of Cabazitaxel can be decreased when combined with Fluconazole.Approved
FludarabineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fludarabine.Approved
FlumequineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Flumequine.Withdrawn
FluorouracilThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fluorouracil.Approved
FlutamideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Flutamide.Approved
FluvoxamineThe metabolism of Cabazitaxel can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Formestane.Approved, Investigational, Withdrawn
FormycinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Formycin.Experimental
FosamprenavirThe metabolism of Cabazitaxel can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Cabazitaxel can be increased when it is combined with Fosaprepitant.Approved
FosbretabulinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fosbretabulin.Investigational
FosphenytoinThe metabolism of Cabazitaxel can be increased when combined with Fosphenytoin.Approved
FotemustineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fotemustine.Experimental, Investigational
FulvestrantThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fulvestrant.Approved, Investigational
FumagillinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fumagillin.Experimental
Fusidic AcidThe serum concentration of Cabazitaxel can be increased when it is combined with Fusidic Acid.Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Cabazitaxel.Investigational
Gallium nitrateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Gallium nitrate.Approved, Investigational
GarenoxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Gatifloxacin.Approved, Investigational
GefitinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Gefitinib.Approved, Investigational
GeldanamycinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Geldanamycin.Experimental, Investigational
GemcitabineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Gemcitabine.Approved
GemifloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Gemifloxacin.Approved, Investigational
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Gemtuzumab ozogamicin.Approved
GenisteinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Genistein.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Cabazitaxel.Investigational
Ginsenoside CThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ginsenoside C.Nutraceutical
GitoformateGitoformate may decrease the cardiotoxic activities of Cabazitaxel.Experimental
GoserelinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Goserelin.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Grepafloxacin.Investigational, Withdrawn
GS 0573The risk or severity of adverse effects can be increased when Cabazitaxel is combined with GS 0573.Investigational
GusperimusThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Gusperimus.Investigational
HadacidinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Hadacidin.Experimental
HalofuginoneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Halofuginone.Investigational, Vet Approved
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cabazitaxel.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Cabazitaxel.Approved, Withdrawn
HexestrolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Hexestrol.Withdrawn
Hydroxyprogesterone caproateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Hydroxyprogesterone caproate.Approved
HydroxyureaThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Hydroxyurea.Approved
HypericinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Hypericin.Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ibrutinib.Approved
IdarubicinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Idarubicin.Approved
IdelalisibThe serum concentration of Cabazitaxel can be increased when it is combined with Idelalisib.Approved
IfosfamideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ifosfamide.Approved
ImatinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Imatinib.Approved
ImiquimodThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Imiquimod.Approved, Investigational
IndinavirThe serum concentration of Cabazitaxel can be increased when it is combined with Indinavir.Approved
IndirubinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Indirubin.Investigational
Indole-3-carbinolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Indole-3-carbinol.Investigational
InfigratinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Infigratinib.Investigational
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Cabazitaxel.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Cabazitaxel.Investigational
IniparibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Iniparib.Experimental, Investigational
Interferon Alfa-2b, RecombinantThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Interferon Alfa-2b, Recombinant.Approved
Interferon beta-1aThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Interferon beta-1a.Approved, Investigational
IobenguaneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Iobenguane.Approved, Investigational
IpilimumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ipilimumab.Approved
IrbesartanThe metabolism of Cabazitaxel can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Irinotecan.Approved, Investigational
IrofulvenThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Irofulven.Investigational
IrsogladineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Irsogladine.Investigational
IsavuconazoniumThe metabolism of Cabazitaxel can be decreased when combined with Isavuconazonium.Approved, Investigational
IsosorbideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Isosorbide.Approved, Investigational
IsradipineThe metabolism of Cabazitaxel can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Cabazitaxel can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Cabazitaxel can be increased when it is combined with Ivacaftor.Approved
IxabepiloneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ixabepilone.Approved, Investigational
IxazomibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ixazomib.Approved
KetoconazoleThe serum concentration of Cabazitaxel can be increased when it is combined with Ketoconazole.Approved, Investigational
KOS-1584The risk or severity of adverse effects can be increased when Cabazitaxel is combined with KOS-1584.Investigational
KRN-7000The risk or severity of adverse effects can be increased when Cabazitaxel is combined with KRN-7000.Investigational
L-alanosineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with L-alanosine.Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Cabazitaxel.Experimental
LanreotideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lanreotide.Approved
LapatinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lapatinib.Approved, Investigational
LCL-161The risk or severity of adverse effects can be increased when Cabazitaxel is combined with LCL-161.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Cabazitaxel.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Leflunomide.Approved, Investigational
LenalidomideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lenalidomide.Approved
LentinanThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lentinan.Experimental, Investigational
LenvatinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lenvatinib.Approved
LetrozoleThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Letrozole.Approved, Investigational
LeuprolideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Leuprolide.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Levofloxacin.Approved, Investigational
LiarozoleThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Liarozole.Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lomefloxacin.Approved, Investigational
LometrexolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lometrexol.Investigational
LomustineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lomustine.Approved
LonidamineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lonidamine.Approved, Investigational
LopinavirThe serum concentration of Cabazitaxel can be increased when it is combined with Lopinavir.Approved
LosartanThe metabolism of Cabazitaxel can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Cabazitaxel can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Cabazitaxel can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Cabazitaxel can be increased when it is combined with Lumacaftor.Approved
LurtotecanThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lurtotecan.Investigational
LycopeneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lycopene.Approved
MafosfamideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mafosfamide.Investigational
MannosulfanThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mannosulfan.Experimental
MasitinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Masitinib.Investigational, Vet Approved
MasoprocolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Masoprocol.Approved, Investigational
MaxacalcitolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Maxacalcitol.Approved, Investigational
MebendazoleThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mebendazole.Approved, Vet Approved
MechlorethamineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mechlorethamine.Approved
MedrogestoneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Medrogestone.Approved
Medroxyprogesterone acetateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Medroxyprogesterone acetate.Approved, Investigational
Megestrol acetateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Megestrol acetate.Approved, Vet Approved
MelphalanThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Melphalan.Approved
MequinolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mequinol.Approved
MercaptopurineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mercaptopurine.Approved
MerestinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Merestinib.Investigational
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Cabazitaxel.Investigational, Withdrawn
MethotrexateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Methotrexate.Approved
Methyl aminolevulinateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Methyl aminolevulinate.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Methylprednisolone.Approved, Vet Approved
MethylselenocysteineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Methylselenocysteine.Investigational
MethyltestosteroneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Methyltestosterone.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Cabazitaxel.Experimental
MetoprineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Metoprine.Experimental
MidostaurinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Midostaurin.Approved
MifepristoneThe serum concentration of Cabazitaxel can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Miltefosine.Approved
MisonidazoleThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Misonidazole.Investigational
MitobronitolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mitobronitol.Experimental
MitoguazoneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mitoguazone.Investigational
MitolactolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mitolactol.Investigational
MitomycinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mitomycin.Approved
MitotaneThe serum concentration of Cabazitaxel can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mitoxantrone.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mizoribine.Investigational
MLN576The risk or severity of adverse effects can be increased when Cabazitaxel is combined with MLN576.Investigational
MolgramostimThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Molgramostim.Investigational
motexafin gadoliniumThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with motexafin gadolinium.Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mycophenolic acid.Approved
NadifloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Nadifloxacin.Investigational
Nalidixic AcidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Nalidixic Acid.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Cabazitaxel.Approved
NamitecanThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Namitecan.Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Natalizumab.Approved, Investigational
NavitoclaxThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Navitoclax.Investigational
NebularineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Nebularine.Experimental
NecitumumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Necitumumab.Approved
NedaplatinNedaplatin may increase the myelosuppressive activities of Cabazitaxel.Approved, Investigational
NefazodoneThe serum concentration of Cabazitaxel can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelarabineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Nelarabine.Approved, Investigational
NelfinavirThe serum concentration of Cabazitaxel can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Cabazitaxel can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Cabazitaxel can be increased when combined with Nevirapine.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Niguldipine.Experimental
NilotinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Nilotinib.Approved, Investigational
NilutamideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Nilutamide.Approved
NimustineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Nimustine.Investigational
NintedanibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Nintedanib.Approved
NiraparibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Niraparib.Approved, Investigational
NivolumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Nivolumab.Approved
nocodazoleThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with nocodazole.Experimental
NolatrexedThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Nolatrexed.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Norfloxacin.Approved
NOV-002NOV-002 may increase the myelosuppressive activities of Cabazitaxel.Investigational
ObinutuzumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Obinutuzumab.Approved
OblimersenThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Oblimersen.Experimental, Investigational
OBP-801The risk or severity of adverse effects can be increased when Cabazitaxel is combined with OBP-801.Investigational
OctreotideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Octreotide.Approved, Investigational
OfatumumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ofatumumab.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ofloxacin.Approved
OglufanideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Oglufanide.Investigational
OlaparibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Olaparib.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Cabazitaxel.Experimental, Investigational
OltiprazThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Oltipraz.Investigational
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Omacetaxine mepesuccinate.Approved
OnapristoneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Onapristone.Investigational
OprelvekinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Oprelvekin.Approved, Investigational
OsimertinibThe serum concentration of Cabazitaxel can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Cabazitaxel.Approved
OxaliplatinOxaliplatin may increase the myelosuppressive activities of Cabazitaxel.Approved, Investigational
Oxolinic acidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Oxolinic acid.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cabazitaxel.Approved, Vet Approved
Paclitaxel poliglumexThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Paclitaxel poliglumex.Experimental, Investigational
PalbociclibThe serum concentration of Cabazitaxel can be increased when it is combined with Palbociclib.Approved
PalifosfamideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Palifosfamide.Investigational
PamidronateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pamidronate.Approved
PanitumumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Panitumumab.Approved, Investigational
PanobinostatThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Panobinostat.Approved, Investigational
PatupiloneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Patupilone.Experimental, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Cabazitaxel.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pefloxacin.Approved
PegaspargaseThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pegaspargase.Approved, Investigational
PembrolizumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pembrolizumab.Approved
PemetrexedThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pemetrexed.Approved, Investigational
PenclomedineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Penclomedine.Investigational
PentobarbitalThe metabolism of Cabazitaxel can be increased when combined with Pentobarbital.Approved, Vet Approved
PentostatinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pentostatin.Approved, Investigational
PertuzumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pertuzumab.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Cabazitaxel.Experimental
Phenethyl IsothiocyanateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Phenethyl Isothiocyanate.Investigational
PhenobarbitalThe metabolism of Cabazitaxel can be increased when combined with Phenobarbital.Approved
Phenylacetic acidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Phenylacetic acid.Approved
Phenylbutyric acidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Phenylbutyric acid.Approved, Investigational
PhenytoinThe metabolism of Cabazitaxel can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cabazitaxel.Approved, Investigational
PinometostatThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pinometostat.Investigational
PioglitazoneThe metabolism of Cabazitaxel can be decreased when combined with Pioglitazone.Approved, Investigational
PipobromanThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pipobroman.Approved
PirarubicinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pirarubicin.Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pirfenidone.Approved, Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pirlindole.Approved
PixantroneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pixantrone.Approved, Investigational
PlevitrexedThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Plevitrexed.Investigational
PlicamycinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Plicamycin.Approved, Investigational, Withdrawn
PodofiloxThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Podofilox.Approved
PodophyllinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Podophyllin.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pomalidomide.Approved
PonatinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ponatinib.Approved
Porfimer sodiumThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Porfimer sodium.Approved, Investigational
porfiromycinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with porfiromycin.Investigational
PosaconazoleThe serum concentration of Cabazitaxel can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PralatrexateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pralatrexate.Approved
PrednimustineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Prednimustine.Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Prednisone.Approved, Vet Approved
PrimidoneThe metabolism of Cabazitaxel can be increased when combined with Primidone.Approved, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Procarbazine.Approved
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Cabazitaxel.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Cabazitaxel.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Prulifloxacin.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Puromycin.Experimental
PyrazoloacridineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pyrazoloacridine.Investigational
QuinacrineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Quinacrine.Approved, Investigational
QuinineThe metabolism of Cabazitaxel can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Cabazitaxel can be decreased when combined with Rabeprazole.Approved, Investigational
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Cabazitaxel.Approved
RabusertibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Rabusertib.Investigational
Radium Ra 223 DichlorideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Radium Ra 223 Dichloride.Approved, Investigational
RaltitrexedThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Raltitrexed.Approved, Investigational
RamucirumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ramucirumab.Approved, Investigational
RanibizumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ranibizumab.Approved
RanimustineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ranimustine.Experimental
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Cabazitaxel.Approved, Investigational
RanpirnaseThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ranpirnase.Investigational
RegorafenibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Regorafenib.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Resveratrol.Approved, Experimental, Investigational
Rhodamine 6GThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Rhodamine 6G.Experimental
RidaforolimusThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ridaforolimus.Investigational
RifabutinThe metabolism of Cabazitaxel can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Cabazitaxel can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Cabazitaxel can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Cabazitaxel.Approved, Investigational
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Cabazitaxel.Investigational
RituximabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Rituximab.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Cabazitaxel.Approved
RomidepsinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Romidepsin.Approved, Investigational
RoquinimexThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Roquinimex.Investigational
RosiglitazoneThe metabolism of Cabazitaxel can be decreased when combined with Rosiglitazone.Approved, Investigational
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Cabazitaxel.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Cabazitaxel.Approved
RubitecanThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Rubitecan.Investigational
RucaparibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Rucaparib.Approved, Investigational
RufloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Rufloxacin.Experimental
RuxolitinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ruxolitinib.Approved
SalirasibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Salirasib.Investigational
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Cabazitaxel.Approved
SaquinavirThe serum concentration of Cabazitaxel can be increased when it is combined with Saquinavir.Approved, Investigational
SaracatinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Saracatinib.Investigational
SatraplatinSatraplatin may increase the myelosuppressive activities of Cabazitaxel.Investigational
SecobarbitalThe metabolism of Cabazitaxel can be increased when combined with Secobarbital.Approved, Vet Approved
SeliciclibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Seliciclib.Investigational
SemaxanibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Semaxanib.Investigational
SemustineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Semustine.Experimental, Investigational
SeocalcitolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Seocalcitol.Experimental, Investigational
SildenafilThe metabolism of Cabazitaxel can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Cabazitaxel.Approved
SiltuximabThe serum concentration of Cabazitaxel can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Cabazitaxel can be increased when it is combined with Simeprevir.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cabazitaxel.Approved
SirolimusThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sirolimus.Approved, Investigational
SitafloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sitafloxacin.Experimental, Investigational
SizofiranThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sizofiran.Investigational
SoblidotinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Soblidotin.Investigational
SonidegibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sonidegib.Approved, Investigational
SorafenibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sorafenib.Approved, Investigational
SparfloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sparfloxacin.Approved, Investigational
Sparfosic acidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sparfosic acid.Experimental
SparsomycinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sparsomycin.Experimental
squalamineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with squalamine.Investigational
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Cabazitaxel.Investigational
SRT501The risk or severity of adverse effects can be increased when Cabazitaxel is combined with SRT501.Investigational
St. John's WortThe serum concentration of Cabazitaxel can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Cabazitaxel can be increased when it is combined with Stiripentol.Approved
StreptozocinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Streptozocin.Approved
SulfamethoxazoleThe metabolism of Cabazitaxel can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Cabazitaxel can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulforaphaneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sulforaphane.Investigational
SulindacThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sulindac.Approved
SunitinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sunitinib.Approved, Investigational
SuraminThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Suramin.Approved, Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Cabazitaxel.Approved, Investigational
TalaporfinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Talaporfin.Investigational
TalazoparibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Talazoparib.Investigational
TamoxifenThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tamoxifen.Approved
TaselisibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Taselisib.Investigational
TaurolidineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Taurolidine.Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Cabazitaxel.Investigational
TegafurThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tegafur.Approved
TelaprevirThe serum concentration of Cabazitaxel can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Cabazitaxel can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Temafloxacin.Withdrawn
TemoporfinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Temoporfin.Approved, Investigational
TemozolomideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Temozolomide.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Temsirolimus.Approved
TeniposideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Teniposide.Approved
TeriflunomideThe metabolism of Cabazitaxel can be decreased when combined with Teriflunomide.Approved
TestolactoneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Testolactone.Approved, Investigational
TezacitabineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tezacitabine.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Cabazitaxel.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiotepaThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Thiotepa.Approved
ThymalfasinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Thymalfasin.Approved, Investigational
TiazofurineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tiazofurine.Experimental
TiboloneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tibolone.Approved, Investigational
TiclopidineThe metabolism of Cabazitaxel can be decreased when combined with Ticlopidine.Approved
TioguanineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tioguanine.Approved
Tiomolibdate ionThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tiomolibdate ion.Investigational
TipifarnibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tipifarnib.Investigational
TirapazamineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tirapazamine.Investigational
TivozanibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tivozanib.Investigational
TocilizumabThe serum concentration of Cabazitaxel can be decreased when it is combined with Tocilizumab.Approved
TofacitinibCabazitaxel may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TopiroxostatThe metabolism of Cabazitaxel can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Cabazitaxel.Approved, Investigational
ToremifeneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Toremifene.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tositumomab.Approved, Investigational
ToyocamycinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Toyocamycin.Experimental
TrabectedinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Trabectedin.Approved, Investigational
TrametinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Trametinib.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Cabazitaxel.Approved, Investigational
Trastuzumab emtansineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Trastuzumab emtansine.Approved
TrebananibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Trebananib.Investigational
TremelimumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tremelimumab.Investigational
TreosulfanThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Treosulfan.Investigational
TretazicarThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tretazicar.Investigational
TretinoinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriaziquoneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Triaziquone.Experimental
TrifluridineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Trifluridine.Approved
TrilostaneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TrimethoprimThe metabolism of Cabazitaxel can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimetrexateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Trimetrexate.Approved, Investigational
TriptolideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Triptolide.Investigational
TriptorelinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Triptorelin.Approved, Vet Approved
TrofosfamideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Trofosfamide.Investigational
TrovafloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TroxacitabineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Troxacitabine.Investigational
TubercidinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tubercidin.Experimental
UbenimexThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ubenimex.Experimental, Investigational
Uracil mustardThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Uracil mustard.Approved
VadimezanThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vadimezan.Investigational
ValrubicinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Valrubicin.Approved
VandetanibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vandetanib.Approved
VapreotideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vapreotide.Approved, Investigational
VeliparibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Veliparib.Investigational
VemurafenibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vemurafenib.Approved
VenetoclaxThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Venetoclax.Approved
VenlafaxineThe metabolism of Cabazitaxel can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Cabazitaxel can be decreased when combined with Verapamil.Approved
VerteporfinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Verteporfin.Approved, Investigational
VesnarinoneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vesnarinone.Investigational
VinblastineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Cabazitaxel.Approved, Investigational
VincristineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vincristine.Approved, Investigational
VindesineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vindesine.Approved, Investigational
VinflunineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vinflunine.Approved
VinorelbineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vinorelbine.Approved, Investigational
VintafolideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vintafolide.Investigational
VismodegibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vismodegib.Approved
Vitamin AThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vitamin A.Approved, Nutraceutical, Vet Approved
VoriconazoleThe serum concentration of Cabazitaxel can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vorinostat.Approved, Investigational
VorozoleThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vorozole.Experimental
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Cabazitaxel.Approved
ZiprasidoneThe metabolism of Cabazitaxel can be decreased when combined with Ziprasidone.Approved
ZorubicinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Zorubicin.Experimental
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Cabazitaxel.Approved
Zuretinol acetateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Zuretinol acetate.Investigational
Food Interactions
Not Available

References

Synthesis Reference

Nagesh Palepu, "CABAZITAXEL FORMULATIONS AND METHODS OF PREPARING THEREOF." U.S. Patent US20120065255, issued March 15, 2012.

US20120065255
General References
  1. Galsky MD, Dritselis A, Kirkpatrick P, Oh WK: Cabazitaxel. Nat Rev Drug Discov. 2010 Sep;9(9):677-8. doi: 10.1038/nrd3254. [PubMed:20811375]
  2. Kort A, Hillebrand MJ, Cirkel GA, Voest EE, Schinkel AH, Rosing H, Schellens JH, Beijnen JH: Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Apr 15;925:117-23. doi: 10.1016/j.jchromb.2013.02.034. Epub 2013 Mar 5. [PubMed:23542607]
  3. Nightingale G, Ryu J: Cabazitaxel (jevtana): a novel agent for metastatic castration-resistant prostate cancer. P T. 2012 Aug;37(8):440-8. [PubMed:23091336]
External Links
Human Metabolome Database
HMDB15672
KEGG Drug
D09755
PubChem Compound
9854073
PubChem Substance
99443289
ChemSpider
8029779
ChEBI
63584
ChEMBL
CHEMBL1201748
PharmGKB
PA165958401
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Cabazitaxel
ATC Codes
L01CD04 — Cabazitaxel
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
FDA label
Download (383 KB)
MSDS
Download (99.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentProstate Cancer1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentMetastatic Castration Resistant Prostate Cancer1
1CompletedTreatmentNeoplasms Malignant1
1CompletedTreatmentNeoplasms, Malignant1
1CompletedTreatmentProstate Cancer1
1CompletedTreatmentSolid Cancers1
1CompletedTreatmentTumors, Solid1
1RecruitingTreatmentProstate Cancer1
1RecruitingTreatmentUrothelial Carcinoma of the Urinary Bladder1
1WithdrawnTreatmentProstatic Neoplasms1
1, 2Active Not RecruitingTreatmentProstate Cancer1
1, 2CompletedTreatmentMalignant Neoplasm of Stomach1
1, 2CompletedTreatmentMalignant Solid Tumor - Malignant Nervous System Neoplasm1
1, 2RecruitingTreatmentHormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
1, 2TerminatedTreatmentNeoplasms, Malignant1
1, 2TerminatedTreatmentProstate Cancer / Prostatic Neoplasms1
1, 2WithdrawnTreatmentBrain Cancer1
2Active Not RecruitingTreatmentDistal Esophageal Adenocarcinoma / Gastric Adenocarcinoma / Gastroesophageal Adenocarcinoma1
2Active Not RecruitingTreatmentHormone-Resistant Prostate Cancer / Stage IV Prostate Adenocarcinoma1
2Active Not RecruitingTreatmentMalignant Neoplasm of Stomach1
2Active Not RecruitingTreatmentMetastatic Breast Cancer With Intracranial Metastases1
2Active Not RecruitingTreatmentMetastatic Hormone Refractory Prostate Cancer1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentGlioblastoma Multiforme (GBM) WHO Grade IV1
2CompletedTreatmentHormone Refractory Prostate Cancer1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2CompletedTreatmentMetastatic Castration Resistant Prostate Cancer1
2CompletedTreatmentMetastatic Head and Neck Cancer / Recurrent Head and Neck Cancer1
2CompletedTreatmentMetastatic Hormone Refractory Prostate Cancer1
2CompletedTreatmentPenile Neoplasms1
2CompletedTreatmentProstate Cancer1
2CompletedTreatmentProstatic Neoplasms1
2CompletedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
2CompletedTreatmentTransitional Cell Carcinoma2
2Not Yet RecruitingTreatmentAdrenocortical Carcinoma1
2Not Yet RecruitingTreatmentCancer treatment / Castration-Resistant Prostate Cancer (CRPC) / Circulating Tumor Cells / Prostate Cancer1
2RecruitingDiagnosticCirculating Tumor Cells / Metastatic Hormone Refractory Prostate Cancer1
2RecruitingTreatmentBone Metastatic Prostate Cancer1
2RecruitingTreatmentCancer, Ovarian1
2RecruitingTreatmentHER2 Negative Metastatic Breast Cancer1
2RecruitingTreatmentInfiltrating Bladder Urothelial Carcinoma1
2RecruitingTreatmentLiposarcomas, Dedifferentiated1
2RecruitingTreatmentMetastatic Castration-Resistant Prostatic Cancer1
2RecruitingTreatmentNon-seminomatous Germ-cell Tumors1
2RecruitingTreatmentProstate Cancer2
2RecruitingTreatmentProstate Cancer / Prostate Cancer Aggressiveness1
2RecruitingTreatmentTesticular Cancer1
2SuspendedTreatmentCancer, Breast / Lung Cancers / Progressive Brain Metastases / Recurrent Brain Metastases1
2TerminatedSupportive CareDiarrhea / Hormone-Resistant Prostate Cancer / Recurrent Prostate Cancer / Stage I Prostate Cancer / Stage IIA Prostate Cancer / Stage IIB Prostate Cancer / Stage III Prostate Cancer / Stage IV Prostate Cancer1
2TerminatedTreatmentCancer, Ovarian1
2TerminatedTreatmentColorectal Cancers1
2TerminatedTreatmentEsophageal / Gastrooesophageal Cancer / Malignant Neoplasm of Stomach1
2TerminatedTreatmentProstate Cancer2
2WithdrawnDiagnosticProstatic Neoplasms1
2WithdrawnTreatmentAdvanced Prostate Cancer1
2WithdrawnTreatmentBrain Metastasis / Cancer, Breast / Lung Cancer Non-Small Cell Cancer (NSCLC)1
2WithdrawnTreatmentCastrate-resistant Metastatic Prostate Cancer1
2, 3RecruitingTreatmentMetastasis / Metastatic Hormone Refractory Prostate Cancer1
2, 3Unknown StatusTreatmentTransitional Cell Carcinoma1
2, 3Unknown StatusTreatmentUrothelium Transitional Cell Carcinoma1
3Active Not RecruitingOtherMetastatic Castration Resistant Prostate Cancer1
3Active Not RecruitingTreatmentProstate Cancer1
3CompletedTreatmentMetastatic Hormone Refractory Prostate Cancer1
3CompletedTreatmentNeoplasms / Prostatic Neoplasms1
3CompletedTreatmentProstate Cancer2
3RecruitingTreatmentAdenocarcinoma, Prostate / Progression of Prostate Cancer1
3RecruitingTreatmentMetastatic Hormone Refractory Prostate Cancer1
3TerminatedTreatmentCastrate-resistant Prostate Cancer (CRPC) / Hormone Refractory Prostate Cancer1
4CompletedTreatmentProstate Cancer2
4RecruitingTreatmentMetastatic Hormone Refractory Prostate Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Kit
SolutionIntravenous40 mg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5438072No1994-05-222014-05-22Us
US5698582No2010-06-172012-07-03Us
US6372780No1996-03-262016-03-26Us
US6387946No1996-03-262016-03-26Us
US8927592Yes2011-04-272031-04-27Us
US7241907Yes2006-06-102026-06-10Us
US5847170Yes2001-09-262021-09-26Us
US6331635No1996-03-262016-03-26Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00413 mg/mLALOGPS
logP3.69ALOGPS
logP4.2ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)11.97ChemAxon
pKa (Strongest Basic)-3.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area202.45 Å2ChemAxon
Rotatable Bond Count15ChemAxon
Refractivity213.4 m3·mol-1ChemAxon
Polarizability86.39 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9535
Blood Brain Barrier-0.9825
Caco-2 permeable-0.7945
P-glycoprotein substrateSubstrate0.8287
P-glycoprotein inhibitor IInhibitor0.6646
P-glycoprotein inhibitor IIInhibitor0.5887
Renal organic cation transporterNon-inhibitor0.933
CYP450 2C9 substrateNon-substrate0.8236
CYP450 2D6 substrateNon-substrate0.882
CYP450 3A4 substrateSubstrate0.7256
CYP450 1A2 substrateNon-inhibitor0.8197
CYP450 2C9 inhibitorNon-inhibitor0.8654
CYP450 2D6 inhibitorNon-inhibitor0.8935
CYP450 2C19 inhibitorNon-inhibitor0.8429
CYP450 3A4 inhibitorNon-inhibitor0.6339
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9068
Ames testNon AMES toxic0.8028
CarcinogenicityNon-carcinogens0.9264
BiodegradationNot ready biodegradable0.9926
Rat acute toxicity2.6378 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9907
hERG inhibition (predictor II)Non-inhibitor0.7906
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as taxanes and derivatives. These are diterpenoids with a structure based either on the taxane skeleton, or a derivative thereof. In term of phytochemistry, several derivatives of the taxane skeleton exist: 2(3->20)-abeotaxane, 3,11-cyclotaxane, 11(15->1),11(10->9)-abeotaxane, 3,8-seco-taxane, and 11(15->1)-abeotaxane, among others. More complex skeletons have been found recently, which include the taxane-derived [3.3.3] propellane ring system.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Diterpenoids
Direct Parent
Taxanes and derivatives
Alternative Parents
Benzoic acid esters / Tricarboxylic acids and derivatives / Benzoyl derivatives / Fatty acid esters / Monosaccharides / Tertiary alcohols / Carbamate esters / Secondary alcohols / Oxetanes / Carboxylic acid esters
show 8 more
Substituents
Taxane diterpenoid / Benzoate ester / Benzoic acid or derivatives / Tricarboxylic acid or derivatives / Benzoyl / Fatty acid ester / Monosaccharide / Monocyclic benzene moiety / Benzenoid / Fatty acyl
show 22 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
tetracyclic diterpenoid (CHEBI:63584)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Binder
General Function
Structural constituent of cytoskeleton
Specific Function
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
Gene Name
TUBA4A
Uniprot ID
P68366
Uniprot Name
Tubulin alpha-4A chain
Molecular Weight
49923.995 Da
References
  1. JEVTANA - cabazitaxel [Link]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Binder
General Function
Structural constituent of cytoskeleton
Specific Function
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain (By similarity).
Gene Name
TUBB1
Uniprot ID
Q9H4B7
Uniprot Name
Tubulin beta-1 chain
Molecular Weight
50326.56 Da
References
  1. JEVTANA - cabazitaxel [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. JEVTANA - cabazitaxel [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. JEVTANA - cabazitaxel [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. JEVTANA - cabazitaxel [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. JEVTANA - cabazitaxel [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. JEVTANA - cabazitaxel [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. JEVTANA - cabazitaxel [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da
References
  1. JEVTANA - cabazitaxel [Link]

Drug created on September 14, 2010 10:21 / Updated on November 19, 2017 20:33